Back to top
more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$52.03 USD

52.03
732,290

+0.17 (0.33%)

Updated Aug 16, 2024 04:00 PM ET

After-Market: $52.04 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (149 out of 251)

Industry: Medical Services

Better trading starts here.

Zacks News

AMN Healthcare (AMN) Hits 52-Week High: What's Behind It?

Investors are optimistic about AMN Healthcare's (AMN) broad array of services.

Is AMN Healthcare Services (AMN) Outperforming Other Medical Stocks This Year?

Is (AMN) Outperforming Other Medical Stocks This Year?

AMN Healthcare (AMN) Hits Fresh High: Is There Still Room to Run?

AMN Healthcare (AMN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

AMN Healthcare (AMN) Q2 Earnings Beat Estimates, Margins Up

AMN Healthcare's (AMN) robust Q2 results demonstrate its segmental strength.

AMN Healthcare Services (AMN) Tops Q2 Earnings and Revenue Estimates

AMN Healthcare (AMN) delivered earnings and revenue surprises of 11.56% and 3.39%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

AMN Healthcare (AMN) to Report Q2 Earnings: What to Expect?

Continued strength in AMN Healthcare's (AMN) staffing services is expected to have driven up Q2 sales.

AMN Healthcare Services (AMN) Reports Next Week: Wall Street Expects Earnings Growth

AMN Healthcare (AMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exact Sciences (EXAS) Q2 Loss Wider Than Expected, Revenues Top

Exact Sciences' (EXAS) legacy Screening business sees significant improvement in revenues during the second quarter on Cologuard volume growth.

LabCorp (LH) Q2 Earnings Surpass Estimates, 2021 View Raised

LabCorp (LH) Diagnostics revenues in the second quarter increase significantly on organic Base Business volume improvements despite decelerating demand for COVID-19 testing.

CONMED's (CNMD) Q2 Earnings Surpass Estimates, '21 View Up

CONMED (CNMD) witnesses revenue uptick in both of its segments during Q2 despite continued pandemic-led business disruptions.

NuVasive (NUVA) Q2 Earnings Beat Estimates, Gross Margin Up

NuVasive (NUVA) reports strong segmental and geographical performance driving the top line in second-quarter 2021.

Baxter (BAX) Q2 Earnings Surpass Estimates, Revenues Miss

Baxter's (BAX) second-quarter results reflect robust performance across all its business units.

West Pharmaceutical (WST) Q2 Earnings & Revenues Top Estimates

West Pharmaceutical's (WST) second-quarter earnings reflect strong segmental performance.

Integra (IART) Q2 Earnings Top Estimates, 2021 Guidance Up

Integra (IART) reports better-than-expected revenues with strong segmental performance driving the top line in second-quarter 2021.

Hologic's (HOLX) Q3 Earnings Top Estimates, Q4 View Dull

Impressive performance by the Breast Health and GYN Surgical segments drive Hologic's (HOLX) fiscal third-quarter revenues.

Align Technology (ALGN) Q2 Earnings Top Estimates, 2021 View Up

Strength in Invisalign Clear Aligners and iTero scanners sales volumes during the fiscal second quarter drove Align Technology's (ALGN) top line.

AMN Healthcare Services (AMN) Dips More Than Broader Markets: What You Should Know

AMN Healthcare Services (AMN) closed the most recent trading day at $98.47, moving -0.64% from the previous trading session.

Thermo Fisher (TMO) Beats on Q2 Earnings, Raises 2021 View

Thermo Fisher's (TMO) base business witnesses accelerated growth in the second quarter.

Masimo's (MASI) Q2 Earnings Surpass Estimates, '21 View Up

Masimo's (MASI) robust product shipments, along with strong rebound in sensor sales, drive its Q2 sales.

Stryker (SYK) Q2 Earnings and Revenues Surpass Estimates

Stryker's (SYK) second-quarter earnings reflect strong performance across Orthopaedics, MedSurg and Neurotechnology and Spine segments.

Chemed (CHE) Q2 Earnings & Revenues Top Estimates, Margins Up

Chemed (CHE) reports better-than-expected earnings and revenues with strong Roto-Rooter segment performance driving the top line in second-quarter 2021.

Ecolab (ECL) Q2 Earnings & Revenues Beat Mark, Margins Rise

Ecolab's (ECL) robust performances across majority of its segments drive its Q2 sales despite pandemic-led business challenges.

Boston Scientific (BSX) Q2 Earnings Beat, 2021 Guidance Up

Organic revenues at each of Boston Scientific's (BSX) core business segments and geographies increase in Q2.

PerkinElmer (PKI) Q2 Earnings and Revenues Surpass Estimates

PerkinElmer's (PKI) second-quarter results benefit from strong segmental performance.

Catalent (CTLT) Boosts Portfolio Via Launch of GPEx Lightning

Catalent's (CTLT) latest product is aimed at improving customer service by speeding up the drug substance development process.